The Claim in Context
In June 2025, the Advisory Committee on Immunization Practices (ACIP) voted to recommend banning thimerosal, a preservative, from all vaccines because of its mercury content. Extensive research proves that thimerosal is a safe ingredient in vaccines, and it does not cause neurological problems or autism. Banning vaccine ingredients without solid scientific reasons sets a dangerous precedent and ultimately makes children less safe.
Key Facts
- Thimerosal is an extensively studied preservative used in a small percentage of multi-dose vials of the influenza vaccine administered in the U.S. It has not been in any routine childhood vaccines since the early 2000s.
- Thimerosal is an ethyl mercury. Toxicity concerns relate to methyl mercury, a different form of the element that has never been used in vaccines.
- In 2001, thimerosal was removed from all routine childhood vaccines because misleading claims about different types of mercury were eroding public trust in vaccine safety. Pediatric and medical organizations — including AAP — recommended removing thimerosal because the risks of children going without vaccines had become greater than the benefits of thimerosal as a vaccine ingredient.
- AAP's assessment of the best available evidence has always been, and continues to be, that thimerosal is a safe additive in appropriate amounts.
- Extensive research has demonstrated that thimerosal is safe. There is no evidence that thimerosal causes autism or other neurodevelopmental disorders. Autism rates actually rose after thimerosal was removed from childhood vaccines.
- Decisions about which vaccine ingredients are safe should not be based on disproven presumptions, but rather on medical evidence.
Evidence Snapshot
Numerous studies conducted over many years in multiple countries have confirmed that thimerosal is safe. Banning vaccine ingredients without cause increases the perceived risk of vaccines and fuels vaccine hesitancy.
Experts Say:
“There is no evidence that thimerosal has adverse neurological or neurodevelopmental adverse outcomes when used as a preservative in vaccines. This fact was definitively determined years ago, and the FDA, the CDC, and many academic institutions have excellent reviews of the safety of thimerosal-containing vaccines in children. Raising this topic now has only one purpose- to sow distrust in vaccines in general and in the process to determine vaccine safety.”
— James Campbell, MD, MS, FAAP, Member, AAP Committee on Infectious Diseases
Why It Matters
Pediatricians should be able to trust the ACIP to make evidence-based recommendations to protect children’s health. It is reckless and dangerous for government agencies to undermine public trust in vaccines.
Resources for Further Information
- Annals of Internal Medicine: Maternal Influenza A(H1N1) Immunization During Pregnancy and Risk for Autism Spectrum Disorder in Offspring : A Cohort Study
- JAMA Pediatrics: Association Between Pandemic Influenza A(H1N1) Vaccination in Pregnancy and Early Childhood Morbidity in Offspring
- Pediatrics Volume 126: Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism
- New England Journal of Medicine: Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years
- Pediatrics Volume 114: Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association
- The Journal of Pediatrics Volume 163: Exposure to Antibody-Stimulating Proteins and Polysaccharides in Vaccines Is Not Associated with Risk of Autism
- Pediatrics Volume 114: Thimerosal Exposure in Infants and Developmental Disorders: A Prospective Cohort Study in the United Kingdom Does Not Support a Causal Association
- JAMA Network: Association between thimerosal-containing vaccine and autism
- PDS: Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7–10 years
- Springer Nature Link: Early exposure to thimerosal-containing vaccines and children's cognitive development. A 9-year prospective birth cohort study in Poland
- Pediatrics Volume 115: Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data
- Pediatrics Volume 125: On-time Vaccine Receipt in the First Year Does Not Adversely Affect Neuropsychological Outcomes
- Vaccine Volume 32: Vaccines are not associated with autism:an evidence-based meta-analysis of case-control and cohort studies
- Pediatrics Volume 123: Neuropsychological Performance 10 Years After Immunization in Infancy With Thimerosal-Containing Vaccines
- Vaccine Volume 33: Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder
- Pediatrics Volume 112: Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases
- Neurotoxicology Volume 44: A meta-analysis of the evidence on the impact of prenatal and early infancy exposures to mercury on autism and attention deficit/hyperactivity disorder in the childhood
- Pediatrics Volume 118: Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations
- Pediatrics Volume 112: Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data
- JAMA Psychiatry: Continuing increases in autism reported to California's developmental services system: mercury in retrograde
- AJPM: Autism and thimerosal-containing vaccines: lack of consistent evidence for an association
Last Updated
07/15/2025
Source
American Academy of Pediatrics